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Abstract
Cerebral blood flow (CBF) and oxygen delivery are tightly controlled to meet neuronal
energy demands; however, studying dynamic neurovascular coupling in the human brain
is challenging due to the lack of methods that can measure rapid changes in CBF and tissue
oxygenation. This report presents an in-house-developed hybrid time-resolved nearinfrared spectroscopy/diffuse correlation spectroscopy (TR-NIRS/DCS) device and its use
to track dynamic CBF and tissue oxygen saturation (StO2) responses simultaneously with
sub-second resolution following a vasodilatory stimulus (i.e., a hypercapnic challenge).
Cerebrovascular reactivity (CVR) experiments were performed on 10 healthy participants
(mean age: 27 years) using a computer-controlled gas delivery system to manipulate
breath-to-breath inspired CO2 levels. TR-NIRS and DCS data were acquired continuously
at a sampling frequency of 3 Hz to capture dynamic CBF and oxygenation responses. CVR
measurements derived from oxyhemoglobin and deoxyhemoglobin concentrations were
3.4 ± 2.6 and 3.0 ± 1.9 %/mmHg, respectively. Their dynamic component, a fitted
exponential coefficient that defines the speed of the response as per the hemodynamic
response function, was estimated to be 32 ± 16 and 33 ± 28 seconds. The corresponding
CVR value and dynamic component derived from CBF was 3.5 ± 3.6 %/mmHg and 33 ±
18 seconds. These experiments demonstrated that the optical system had sufficient
temporal resolution to capture the dynamics of the oxygenation and CBF responses to a
vasodilatory stimulus.

Keywords
Time-resolved, near-infrared spectroscopy, diffuse correlation spectroscopy, cerebral,
blood flow, oxygenation, hemoglobin, hypercapnia.
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Summary for Lay Audience
The brain needs a constant flow of blood and oxygen to keep working. The organ’s ability
to react to changes and provide more blood and higher oxygen levels is called the
cerebrovascular reactivity or CVR. This reactivity value is a good sign of how healthy the
brain is, as lower CVR has been measured in patients with diseases such as Alzheimer's.
Conventionally, CVR is determined by letting a subject breath carbon dioxide as this
increases the width of the vessels in their brain, and measuring the resulting increase in
blood flow and consequently, higher oxygen levels. Researchers have several tools at their
disposal to measure this value such as magnetic resonance imaging, ultrasound, and
positron emission tomography. However, newer laser technologies are able to make the
same measurements with several key benefits. These techniques are better as they do not
require injections, take up less space, are relatively inexpensive and make very quick
measurements. This last point is important as fast measurements allow researchers to
analyze the change in blood flow and oxygen as it is happening rather than focusing on just
the total increase of both factors.
This project involves two laser technologies which were modified and combined to
produce a hybrid system that could measure both oxygen content and blood flow
simultaneously in the brain. Such a system has never been developed before for use on
adults. CVR was measured from 10 participants as well as values that define the speed of
their response to the inhaled carbon dioxide. These values matched what has been found in
previous studies using more expensive devices. Scalp contamination was also investigated
with depth-sensitive techniques applied to achieve more signal from the brain.
Overall, this study shows that CVR can be measured by optical systems, specifically these
two simultaneously. Such a unified hybrid system has never been applied to adults, which
opens up many possible applications. One immediate application could be to focus on the
aging populating, measuring CVR in elderly subjects to find signs of early stage
Alzheimer's disease. This could open the doors to a new diagnostic system.
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Chapter 1
1. Introduction
1.1 Clinical Rational
The human brain requires 20% of the body’s total energy resources despite being only 2%
of the total body weight1. With a lack of energy store, careful regulation and maintenance
of proper blood flow is crucial for optimal neuronal function and long-term brain health.
Impaired cerebral hemodynamics can negatively impact nutrient and oxygen delivery,
resulting in a reduction of ATP production. In turn, reduced energy supply can lead to
detrimental structural changes at the synaptic level, possibly affecting normal cognitive
processes2. It is well known that cerebral blood flow (CBF), glucose and oxidative
metabolic rates decrease with age3–6, and disruptions in cerebrovascular function are
suspected to be the underlying cause of such effects. The long term role of insufficient
cerebrovascular function could contribute to neurodegenerative disorders such as
Alzheimer’s disease (AD)7,8. In order to better assess cerebrovascular health in patient
populations, biomarkers have been developed to allow researchers to better quantify
neurovascular degeneration.

1.1.1 Assessment of Cerebrovascular Health
The measurement of CBF or StO2 can provide an understanding of brain health; however,
the simple steady-state measurement of long-term decreases in these parameters are often
just indicative of neuronal death and does not hint at the underlying reasons of such
consequences. A more sophisticated biomarker of brain health would be cerebrovascular
reactivity (CVR), which is the response of the brain’s microvasculature to some
vasodilatory or vasoconstrictive stimulus. This is often measured from the temporal change
in CBF in response to a stimulus. This physiological parameter is thought to be an
important index of the brain's vascular health and has been studied in great detail with
patients suffering from arterial disease9–13 and stroke12,14. Although plaques on the brain
are the hallmark of AD, there is growing evidence that CVR is also impaired in these
patients15–17. These plaques are made from a build-up of soluble amyloid beta, a symptom
1

that appears relatively late into the onset of AD. Vascular dysregulation of the neuronal
micro-environment and subsequent CVR impairment could be detected earlier, possibly
allowing enough time for preventative measures such as long term exercise to be more
effective8. In addition to being a diagnostic tool for cerebrovascular pathophysiology,
measuring CVR under a wide variety of circumstances could provide researchers with a
better understanding of how the cerebral vasculature controls the distribution of blood flow
for metabolic homeostasis. As of now, this is still a developing field due largely due to the
lack of reliable and portable devices that can measure CVR in unrestricted environment.
Briefly reviewing the current technologies used to assess CVR will provide a great
backbone to the crux of this thesis and allow for an overall understanding of the
methodology available to researchers today.

1.2 Neuromonitoring Techniques for CVR Measurement
1.2.1 Positron Emission Tomography
Position Emission Tomography utilizes an injected radioligand to form images of various
physiological functions. In terms of neuroimaging, it has a multitude of applications
including measuring the oxygen extracted by brain tissue from the blood and mapping
receptor systems such as dopamine and benzodiazepine18,19. One of the more valuable
capabilities of PET in the context of studying CVR is the measurement of CBF, done with
the use of radiolabeled water or [15O]-water injected into the body. By examining the
perfusion response within the cerebral vasculature to some hemodynamic stimulant, a
measure of CVR can be determined20,21. Fierstra et al. provides a recent application of PET
in this context in which CVR impairment was measured in patients suffering from carotid
atherosclerosis22. CBF was measured before and after an injection of acetazolamide – a
drug that increases CBF by inhibiting carbonic anhydrase23. The rate of change in the blood
flow provides a measure of CVR. While PET is considered the clinical gold standard for
hemodynamic imaging, its application to measuring CVR includes the use of radioactivity
and the need for a cyclotron close to the imaging facilities to generate the short half-life
tracer18.
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1.2.2 Functional Magnetic Resonance Imaging
Functional magnetic resonance imaging (fMRI) is the most established and widely used
approach for imaging brain function24,25. The technique measures oxygenation by taking
advantage of the blood oxygen-level dependent (BOLD) signal, a value that is proportional
to the concentration of deoxyhemoglobin24–28. The change in the BOLD signal relative to
the quantity of some neurovascular stimulant provides a direct measure of CVR29,30. The
utility of fMRI for mapping CVR has been applied to stroke patients14, brain injury31,32,
and brain tumors27,33. These techniques primarily focus on the inhalation of CO2
(hypercapnia challenge) as a vasodilatory stimulus and the measurement of end-tidal CO2
to compare to the recorded BOLD response. The use of a safe and standardized CO2
stimulus to induce measurable hemodynamic changes in the brain will be mentioned
multiple times throughout this thesis, as it is often applied in cerebral studies to obtain
measurements of CVR due to its potency in causing vasodilation29,34. Often a simpler
breath-hold paradigm for CO2 accumulation is employed35, as both of these methods have
been established as reproducible and reliable techniques among healthy young controls36,37.
Although less equipment is needed, the breath-hold method requires active subject
cooperation that could lead to poor compliance38, and does not provide a measurement of
CO2 accumulated.
Functional MRI has clear benefits, as it can measure the whole brain with high spatial
resolution without the need for an exogenous contrast agent. Unfortunately, MRI is
expensive which is a limitation for repeat or longitudinal studies39. In addition, the BOLD
response reflects a complex interplay among several hemodynamic and metabolic
parameters, including CBF, blood volume, the metabolic rate of oxygen, and hematocrit;
resulting in an indirect measure of CVR. The BOLD signal is also generally dominated by
large-vessels at clinical field strengths of 1.5 or 3 Tesla7. Finally, due to the physical
enclosure of the device itself and the high magnetic fields, customized stimulus delivery
(such as delivery of a breathable stimulant) and subject response systems (i.e. microphones
and screens to observe subject responses during functional studies) are required for
experiments, limiting flexibility and complicating research25. A different handheld imaging
technique is used when mobility is preferred over whole brain imaging, which will be
discussed in the next section.
3

1.2.3 Transcranial Doppler Ultrasonography
Transcranial Doppler Ultrasound is a mobile modality, commonly used for non-invasive
measurement of blood flow velocity40–42. It allows for the assessment and monitoring of
blood flow, and thus is an excellent technology for clinical and research uses. Parameters
such as cerebral autoregulation and critical closing pressure can be assessed with TCD, and
it can also be used to perform functional tests for evaluating CVR43,44. Several studies have
utilized this technology to evaluate CVR in a wide range of contexts including the simple
measurement and characterization of healthy adults of varying ages45,46, to the analysis of
patients suffering from migraines47, carotid artery disease13 and traumatic brain injury31.
CVR impairment was measured as a value of vasomotor reactivity, which is defined as a
percent change in blood flow velocity in response to – in these studies – a hypercapnic
change.
Despite its uses, TCD focuses on blood flow in the large vessels rather than the
microvasculature. Estimates of cerebral microcirculation health can only be inferred from
these measurements. It is the microcirculation where oxygen delivery occurs and it is the
first component of the vasculature that is typically compromised by disease48, so the lack
of direct microvasculature flow measurement is a significant limitation of the technology.
Also, TCD measurements are operator dependent, making its use reliant on operator
expertise and patient cooperation; this also makes prolonged continuous monitoring
difficult. In addition, the use of TCD may not even be applicable in 10-15% of patients due
to a lack of ultrasound transmission windows41.

1.3 Near-Infrared Spectroscopy
A promising alternative to TCD is near-infrared spectroscopy (NIRS), which is an optical
technique that passes light through a medium to measure its wavelength-specific absorption
properties. When applied to living tissue, the information can be used to measure tissue
oxygenation. Consider the three primary endogenous pigmented compounds in tissue:
oxyhemoglobin (HbO2), deoxyhemoglobin (Hb) and water. The use of near-infrared light
over other wavelength ranges originates from the relatively low absorption of these three
molecules. As a result, penetration of light can reach centimeters in depth49. This specific
4

wavelength range between 700 and 950 nm is considered the first optical window as
wavelengths shorter than 700 nm are highly absorbed by Hb; too much for light to travel
any meaningful distance. The same is true for the absorption of water at wavelengths
greater than 950 nm. In biological tissues, there does exist a second and third optical
window between 1100-1350 nm and 1600-1870 nm, respectively, that could potentially be
utilized as well50, but laser sources that can emit light at these ranges at the powers required
for such systems are not cost-effective51; and thus, most clinical NIRS applications use the
first optical window.
Figure 1.1 displays the absorption spectra of these chromophores, showcasing the first
optical window at which absorption is at a local minimum. The spectral features of HbO2
and Hb allow the concentrations of these chromophores to be derived by quantifying the
amount of near-infrared light absorption at specific wavelengths within the optical window
(see Section 1.3.1 for more details). By quantifying tissue chromophore concentrations, a
value of oxygenation can be derived52.

Figure 1.1: Molar extinction coefficients for the three major chromophores of tissue (Water, Hb, and HbO2)
in the near-infrared range. Values for water has been multiplied by 106 for visibility53.

The first use of NIRS for the specific purpose of brain tissue oxygenation measurement
dates back to 1977 when it was reported that brain tissue had relatively high transparency
5

in the near-infrared range, allowing for the non-invasive detection of hemoglobin via
optical methods. Subsequently, the first prototype NIRS instruments were utilized to
measure cerebral oxygenation in animal models as well as humans in the early to mid 80s.
In 1989, the first commercial NIRS system was built by Hamamatsu Photonics
(Hamamatsu City, Japan); the first of what will become many instruments that represent
over a decade’s worth of research and development. The non-invasiveness, as well as the
easy integration into clinical care, has made this technology an attractive choice for a
multitude of cerebral studies and applications54. Section 1.4 discusses advancements in
NIRS technology.
NIRS has been used to measure CVR in a multitude of clinical contexts, including head
injury patients55 and those suffering from migranes47,56. Age-related effects on CVR has
been investigated with mixed findings57,58. CVR is indirectly assessed by measuring
oxygenation changes, rather than directly measuring blood flow. One key benefit of NIRS
is its high temporal resolution; the capability of sub-second measurements allows for the
dynamic measurement of CVR. This is fast enough to observe and characterize the rate of
change in oxygenation rather than examining only a steady state response. However, scalp
contamination is a limitation due to potential oxygenation changes that occur in the
superficial regions (scalp and skull). Although essential for the metabolic supply of the
skin along with regulation of local and global body temperature59, it will negatively affect
any optical cerebral measurement with noise and artifacts.

1.3.1 Physical Principals of Near-Infrared Spectroscopy
When traveling through a medium, light is attenuated by two main interactions: absorption
and scattering. As shown in Figure 1.1, the amount of light absorption is governed by the
wavelength-dependent absorption properties of the various different chromophores within
the tissue. Since the extent of absorption is proportional to chromophore concentration, this
factor is what is most relevant in the NIRS applications discussed in this thesis. However,
it is important to note that scattering is the dominant interaction between NIR light and
tissue. This section will discuss the physics of these interactions in the application of NIRS.

6

Explaining the interaction in more detail: absorption of a photon happens when an
absorbing molecule within the medium is excited to a higher state after the photon interacts
with it. This typically occurs if the frequency of the photon equals the energy required to
excite a molecular bond to transition to a higher energy state. A scattering event occurs
when the higher energy state is not maintained, and the dipole moment drops back down
to its previous level, resulting in the remission of the photon back into the medium. This is
called Rayleigh Scatter, one of the three types of scattering events that occur within tissue
in the near-infrared range. Mie Scatter, occurring more frequently, happens when light
scatters off larger structures with sizes similar to the wavelength of light. Finally, at the
interfaces between media of differing indices of refraction, Fresnel Reflection occurs. This
is a reflection of a portion of the incident light. When considering light in the near-infrared
range traveling through tissue, Mie scattering and Fresnel reflection are the more common
mechanism of light scattering. The values that define scattering and absorption are
characterized by their respective exponential coefficients: μs for scattering and μa for
absorption. These coefficients are the reciprocal of the average distance a photon will travel
before it is either scattered or absorbed60.
The attenuation of light was first described by Pierre Bouguer in 1729 with a published
paper on the loss of light intensity after its travelled through a medium. Decades later,
another scientist by the name of Johann Heinrich Lambert stated that attenuation of light
traveling through a homogenous sample is directly proportional to its thickness.
Mathematically, if one considered the fraction of light absorbed to be equal to the thickness
of non-scattering material multiplied by the absorption coefficient, the following formula
is determined:
𝑑𝐼
= 𝜇𝑎 𝑑𝑙
𝐼

(1.1)

Here, dI/I is the fraction of light absorbed while dl is the thickness of an infinitesimally
small layer. This can be integrated to derive the Lambert-Bouguer law:
𝐼 = 𝐼𝑜 𝑒 −𝜇𝑎𝑙

(1.2)

Much later in 1852, August Beer discovered that the attenuation of light is proportional to
the concentrations of the attenuating species in the sample. This allows the above equation
to also be written in terms of concentration.
7

𝐼 = 𝐼𝑜 𝑒 −𝜀𝑐𝑙

(1.3)

Here, 𝜀 is the molar extinction coefficient of the chromophore and c is its concentration. In
practical applications, the concentration can be calculated from a measurable absorbance
value, A, via the Beer-Lambert Law:
𝐼
𝐴 = −log ( ) = 𝜇𝑎 𝑙 = 𝜀 ∙ 𝑐 ∙ 𝑙
𝐼𝑜

(1.4)

With the presence of multiple different light absorbers within the medium, this formula can
be linearly extended to include contributions of each though a summation as such:
𝐴 = 𝑙 ∙ ∑ 𝜀𝑖 ∙ 𝑐𝑖

(1.5)

𝑖

In order to describe the attenuation of light due to scattering, formula 1.2 can be modified
with the scattering coefficient.
𝐼 = 𝐼𝑜 𝑒 −𝜇𝑠𝑙

(1.6)

It is important to consider the directionality of the scattering event, and to do this, the
Henyey-Greenstein Phase Function can be employed. It is a probability density function
that describes the likelihood (p(θ)) of a scattering event at a certain angle (θ):
1
1 − 𝑔2
𝑝(𝜃) =
4𝜋 (1 + 𝑔2 − 2𝑔𝑐𝑜𝑠𝜃)3/2

(1.7)

In the formula above, 𝑔 is the Anisotropy Factor; a medium-dependent value that indicates
the forwardness of the scatter. Mathematically it is described as the statistical mean cosine
of the scattering angle, ranging from -1 to 1. A 𝑔 value of 0 represents isometric scattering,
in which photons have minimal directionality after a scattering event; and a high value of
0.9 represents a medium at which photons scatter primarily in the forward direction. For
near-infrared light propagating in tissue, due to the high quantity of scattering events, any
form of directionality is rapidly lost. In this case, the light can be described as a photon
cloud diffusing through the medium. Here, in what is called the ‘diffusive regime’, light
scattering can be characterized by the Reduced Scattering Coefficient:
𝜇′𝑠 = 𝜇𝑠 (1 − 𝑔)

8

(1.8)

In order to obtain an adequate measurement concentration of tissue chromophores, the
dominant effect of light scattering needs to be accounted for. This is done by modifying
the Beer-Lambert law as such:
𝐴 = 𝐷𝑃 ∙ ∑ 𝜀𝑖 ∙ 𝑐𝑖 + 𝐺

(1.9)

𝑖

This equation is appropriately called the Modified Beer-Lambert Law. Here, DP is the
differential pathlength, which takes into account the additional distance traveled by light
when you consider the multiple scattering events. This pathlength depends on the optical
properties of the interrogated media and will always be greater than the source-detector
distance (SDD). G is a scaler term dependent on the wavelength, that represents the
proportion of light that is not detected due to scatter. Unfortunely, without quantifying the
differential pathlength, the concentrations, 𝑐𝑖 , cannot be calculated. In order to obtain DP
(and thus determine the concentrations), techniques have been developed that allow for the
effects of scatter to be considered. This involves modeling of light transport in tissue which
will be discussed in the next section.

1.3.2 Modeling Light Propagation in Tissue
The behaviour of near-infrared light in tissue, as with all electromagnetic radiation, is
dictated by the physics described by Maxwell’s equations. However, in heterogeneous and
highly scattering media, the analytical solutions to these equations are impossible to obtain.
This issue can be overcome by describing the light as discrete photons that are elastically
scattered and absorbed, governed by the Radiative Transfer Equation (RTE):
[

1𝜕
+ 𝑠̂ ∙ ∇ + 𝜇𝑎 + 𝜇𝑠 ] 𝐿(𝜌, 𝑡, 𝑠̂ ) = 𝜇𝑠 ∫4𝜋 𝐿(𝜌, 𝑡, 𝑠̂ )𝑃(𝑠̂ , 𝑠̂ ′ )𝑑𝛺 ′ + 𝑆(𝜌, 𝑡, 𝑠̂ )
𝑣 𝜕𝑡

(1.10)

Here, L(ρ,t,s) is the radiance in the medium as a function of source-detector distance ρ, in
the direction defined by the unit vector 𝑠̂ . The other parameters include v which is the
velocity of light in the medium, 𝑃(𝑠̂ , 𝑠̂ ′ ) which is the scattering phase function, 𝑆(𝜌, 𝑡, 𝑠̂ )
which is the source term that represents the power injected into a unit volume within the
solid angle surrounding 𝑠̂ . The RTE maintains the conservation of energy within a medium
when equating the left and right sides. Outside of biomedical applications, this equation
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has also been used to describe processes in a wide variety of subjects including nuclear
physics, remote sensing, atmospheric science, and astrophysics61.
Assuming the radiance is nearly isotropic (satisfied by replacing μs with μ′s), the quantity
of scattering events is much greater than absorbance events (μ′s >> μa) and that the sourcedetector distance is relatively large, the RTE can be greatly simplified. These assumptions
(called the Diffusion Approximation) are valid for light traveling through biological tissues
at a distance long enough to enter the diffusive regime at which multiple scatting events
have occurred resulting in a lack of directionality to the light. The diffusion approximation
for light transport under these assumptions is the following:
(

1𝜕
− 𝐷∇2 + 𝜇𝑎 ) 𝛷(𝜌, 𝑡) = 𝑆(𝜌, 𝑡)
𝑣 𝜕𝑡

(1.11)

Here, Φ is the fluence and D is the photon diffusion coefficient:
𝐷≡

1
1
≡
3[(1 − 𝑔)𝜇𝑠 + 𝜇𝑎 ] 3(𝜇𝑠 ′ + 𝜇𝑎 )

(1.12)

Analytical solutions are available for defined geometries and boundary conditions. These
solutions assume the source to be an isotropic point and the scattering to be entirely
isotropic within the medium, simplifying the phase function to a constant factor. Under the
assumption that the source can be represented by an infinitesimal short pulse of light, the
time-dependent solution to the diffusion approximation for an infinite medium is62:
3

𝜌2

𝛷(𝜌, 𝑡) = 𝑣(4𝜋𝐷𝑡)−2 ∙ 𝑒 𝜇𝑎 𝑣𝑡 ∙ 𝑒 −4𝜋𝐷𝑡

(1.13)

Here, v is the speed of light within the medium.

1.4 Near-Infrared Techniques
There are two methods of collecting NIRS data, transmission and reflectance mode.
Transmission mode utilizes a source and detector placed on either side of the medium,
allowing light to pass from the source, through the medium, and to the detector. This
method does not rely on the reflectance of light and is only feasible with small sample sizes
due to the relatively limited penetration depth of light in tissue. Transmission mode NIRS
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has been utilized in several food and drug applications63–66, but maintains clinical relevance
only for the measurement of smaller body parts such as fingers. This is not feasible for in
vivo brain tissue measurement (with the exception of some premature neonates) due to the
size of the human head. Reflectance mode, however, utilizes a source and detector adjacent
to one another on the same side of the medium. Here, reflected photons that scatter back to
the surface are collected for analysis. This is possible due to scattering being the dominant
factor in the transport of photons within tissue, typically 100 times more probable than
absorption67.

Figure 1.2: Visualization of Transmission Mode and Reflectance Mode NIRS.

This section will discuss the current near-infrared methods that utilize reflectance mode for
the purpose of in vivo cerebral measurement.

1.4.1 Continuous-Wave Near-Infrared Spectroscopy
The earliest form of NIRS – and the simplest – is Continuous-Wave NIRS (CW-NIRS).
These systems are inexpensive, can be miniaturized to small wireless devices68,69, and thus
a vast majority of NIRS applications are conducted with CW technology70. As the name
suggests, the intensity of the light source is constant (i.e., is not either modulated nor
pulsed). With the use of two or more wavelengths, the system is capable of tracking
changes of Hb and HbO2 by measuring changes in detected light intensity. This approach
only allows for relative measures of hemoglobin concentrations, as the information
provided is not sufficient enough to determine absolute values of both absorption and
scattering. These measurements of relative concentrations are still helpful enough for many
applications such as functional studies and brain mapping (optical tomography)54.
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To determine absolute concentrations of hemoglobin, a technique called Spatially
Resolved Spectroscopy (SRS) was developed and first demonstrated in 1995 by Matcher
et al71. This technique works by acquiring absorption measurements at multiple SDDs.

Figure 1.3: Schematic diagram of Spatially Resolved NIRS where the distance ρ1 < ρ2.

With the additional data provided from a second detector at a different SDD, the absorption
coefficient can be extracted by assuming the scattering coefficient71–73.
The use of multiple SDDs (specifically one short and long SDD) has another application.
Considering the human head is an heterogenous medium, it can be represented as a layered
structure. In such a multi-layered model, two main compartments can be distinguished:
extracerebral tissues (i.e. scalp, skull, etc.) and the cerebral cortex. In the context of depthsensitivity, utilizing multiple SDDs is beneficial as it allows the measurement of the
extracerebral layer alone (with a short SDD) along side the measurement of all layers (with
a long SDD). This allows for some level of differentiation between the layers.
Many commercial devices use this technology to determine a measurement for absolute
oxygenation; however, numerous studies have reported significant differences between
measured StO2 values between multiple devices74–76. These differences could arise from
variation in sensor geometry, scaling methods or calibration procedures. Regardless,
differences between measurements of various commercial NIRS systems suggest that they
are more suited to monitor relative changes and trends in oxygenation. Reliable and
reproducible StO2 measurements are required for proper non-invasive cerebral monitoring
in a clinical setting or during experimentation, as it may be difficult to define normal ranges
and thresholds for different subjects when simply monitoring change. To achieve this, more
advanced NIRS techniques have been developed as discussed in the next two sections.
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1.4.2 Frequency-Domain Near-Infrared Spectroscopy
To discriminate between the effects of light absorption and scattering in tissue, it is
necessary to acquire more than just measurements of intensity. Frequency-Domain (FD)
NIRS measures the amplitude changes and phase shift of intensity-modulated light after
propagation through a medium. To obtain these measurements, the intensity and phase shift
needs to be recorded at least two SDDs77. The following figure visualizes the change in
both phase and intensity of light as it passes through a sample. The analysis of the phaseshift provides information on the total distance that the light has travelled through the
sample78. This allows for absolute optical property measurements and is also directly
correlated to the depth of the light’s propagation into tissue; allowing for depth-sensitive
analysis of optical properties in the extra and intra-cerebral tissue regions.

Figure 1.4: Schematic Diagram of FD-NIRS displaying the change in intensity (I) and phase (Ø) after passing
through a medium.

This technology was first reported in 1990 and was first utilized in vivo on the human head
5 years later54. Since then, research has been ongoing to continue the development of FDNIRS as this technology has multiple advantages mentioned earlier. However, these
advantages come at the cost of increased complexity. Because of this, clinically accepted
oximeters have relied on CW-NIRS technologies. Also, FD-NIRS relies on calibrated
multi-distance measurements further complicating its clinical use, and may be negatively
affected by the tissue heterogeneity79. In order to provide richer depth-sensitive data
capable of determining absolute values of optical properties without the required use of
multi-distance measurements, a different NIRS technique has been developed which is
discussed in the next section.
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1.4.3 Time-Resolved Near-Infrared Spectroscopy
Time-Resolved (TR) NIRS is more complex than CW and FD-NIRS, but offers the
advantage of greater depth-sensitivity, thus providing cerebral oxygenation estimates with
even less extracerebral contamination. Similar to FD-NIRS, TR-NIRS can measure
absolute optical properties. In addition, it is capable of distinguishing late arriving photons
from early arriving ones. This is important – as Figure 1.5 demonstrates – depth-sensitivity
is based on the principle that photons which only interrogate the superficial tissue will have
a shorter time of flight (TOF) compared to the later-arriving photons. The system utilizes
lasers capable of pulsing light at extremely short time scales, usually of the order of
picoseconds in duration, that illuminate the tissue millions of times a second. Extremely
time-sensitive detectors measure photon arrival times and produce a histogram, called a
Temporal Point Spread Function (TPSF) but also sometimes referred to a Distribution of
Times of Flight (DTOF). The TPSF collected by the system is considered to contain the
richest information on the medium’s optical properties in comparison to its CW and FD
counter-parts owing to it’s time-domain modality, and thus has the greatest potential for
use both research and clinical settings80.

Figure 1.5: Schematic Diagram of TR-NIRS. On the left, visualizing the distributive effect of photon arrival
times on the picosecond timescale after a pulse of light traveled through the medium. On the right, the
differentiation of depth within the tissue (scalp, skull, and cortex layers shown) by utilizing temporal data
collected by the system.

This technology was first demonstrated on an animal model back in 198881 and human
subjects in 199282. Since then, several drawbacks have been noted as these systems were
quite bulky, relatively expensive, and require long warm-up times (potentially equal to or
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greater than 60 min) for its pulsed lasers to achieve the steady-state operation83,84. The
drawbacks of TR-NIRS systems described here still exist to some extent and have not been
resolved completely, but improvements and developments of the TR-NIRS technique have
been progressing steadily; which could lead to less expensive, smaller and more robust
instruments eventually resulting in wider adoption of the technology80.
By modeling the TPSF by the diffusion approximation (Equation 1.11), the absolute optical
properties can be extracted85 using the solution provided in Section 1.3.2 (Equation 1.13).
This equation is mathematically modeled with the measured TPSF allowing for
quantitative estimates of the tissue optical properties. The mean TOF can be used to
determine a value for the DP since the speed of light in tissue is known. With this
information, chromophore concentrations can be derived, and thus an absolute
measurement of oxygenation is obtained. Due to the fast firing lasers, sensitive detectors
and timing controls that are required, TR-NIRS is more expensive and technically
advanced than FD-NIRS. Currently TR-NIRS is primarily used as a research tool, however
advancements in this technology is expected to lead to eventual clinical translation.
To take advantage of TR-NIRS’s depth sensitivity, moment analysis of the TPSFs can be
utilized to acquire measurements. This is done with the analysis of the statistical (zeroth,
first, and second; or N, <t>, and V) moments of the measured TPSFs. The zeroth moment
reflects total light intensity, analogous to CW-NIRS, whereas the higher moments have
greater sensitivity to late-arriving photons due to the positive skewness of the TPSF86–88.
As a result, changes in oxygenation obtained by the first and second moment will contain
less extracerebral contamination.

1.5 Optical Blood Flow Techniques
As mentioned before, the ability to measure oxygenation in tissue has many applications
in neuroscience research and the clinic; however, this metric is dependent on both blood
flow and tissue oxygen demand. Blood flow measurements are important as they are the
main components of CVR analysis, and that a number of published papers connect CBF to
the neural response due to neurovascular coupling (NVC)89,90. In addition, it can be utilized
along with oxygenation data to allow researchers to estimate oxidative metabolism
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allowing for a better evaluation of CVR. In a clinical setting, CBF enables clinicians to
distinguish between conditions such as hypoxia and ischemia, to avoid hyperperfusion
injury, and to classify different types of hypoxia91, so there are major applications related
to measuring CBF. This section will outline methods for near-infrared techniques for
measuring blood flow.

1.5.1 Blood Flow Measurement with Near-Infrared Spectroscopy
One approach for measuring CBF is to use an exogenous optical contrast agent, such as
indocyanine green, as an intravascular contrast agent. This technique provides estimates of
absolute CBF and has been validated in experimental animal models92–94 and have been
used extensively in patient studies in a wide variety of applications95–99. However, since it
requires an injection of contrast agent to estimate CBF, it cannot be employed for
continuously monitoring. Another NIRS-based technique is Coherent Hemodynamics
Spectroscopy, which derives CBF based on modelling the phase relationship between oxy
and deoxyhemoglobin100,101. Although it has the potential to provide continuous
monitoring, this approach is indirect and CBF estimates are very dependent on the accuracy
of the underlying model.

1.5.2 Blood Flow Measurement with Diffuse Correlation Spectroscopy
Diffuse Correlation Spectroscopy (DCS) is a relatively new technique for non-invasive
measurement of blood flow in the microvasculature. This technique shares many
advantages with NIRS such as deep tissue penetration, portability, excellent timeresolution, and operator-independent continuous monitoring102. DCS uses a long coherence
length source and measures the decorrelation time scale of the intensity fluctuations of
scattered light, which relates to the motion of moving scattering bodies within the tissue,
mostly consisting of red blood cells (RBCs). Faster moving RBCs lead to a rapid loss of
coherence, which is characterized as a faster decrease in the measured autocorrelation
function. This allows the system to directly measure changes in blood flow103–105.
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Figure 1.6: A) Schematic of the multiple scattering events that occur within the interrogated tissue. The red
circles represent moving RBCs within the microvasculature. B) The intensity fluctuations that are measured
in the microsecond time scale. C) Visualization of the correlation decay over time (Autocorrelation Curve),
and its dependency on the blood flow speed106.

Similar to Section 1.4.3, since DCS is a major topic of this thesis, it is helpful to review the
physics of how this technology works.
Consider the temporal autocorrelation function 𝐺1 (𝜌, 𝜏) of an electromagnetic field 𝐸(𝜌, 𝑡)
in a scattering medium for a given source-detector distance 𝜌:
𝐺1 (𝜌, 𝜏) = 〈𝐸(𝜌, 𝑡) ∙ 𝐸(𝜌, 𝑡 + 𝜏)〉

(1.14)

The 〈〉 brackets denote the time averages (for experiments) or ensemble averages (for
calculations), i.e. the mean of a function that defines a microstate of a system. Here, 𝜏 is
the autocorrelation delay time and 𝐸(𝜌, 𝑡 + 𝜏) is the field after a delay time 𝜏. Normalizing
the above equation to obtain 𝑔1 (𝜌, 𝜏):
𝑔1 (𝜌, 𝜏) =

〈𝐸(𝜌, 𝑡) ∙ 𝐸 ∗ (𝜌, 𝑡 + 𝜏)〉
〈|𝐸(𝜌, 𝑡)|2 〉

(1.15)

Rather than considering an electromagnetic field, DCS works by considering the
autocorrelation function of light intensity detected as a function of time, I(𝜌, 𝑡):
𝑔2 (𝜌, 𝜏) =

〈I(𝜌, 𝑡) ∙ 𝐼 ∗ (𝜌, 𝑡 + 𝜏)〉
〈|𝐼(𝜌, 𝑡)|2 〉

(1.16)

The system measures this autocorrelation function from the collected intensity fluctuations
over time. 𝑔2 is related to 𝑔1 via the Siegert relationship107:
𝑔2 (𝜌, 𝜏) = 1 + 𝛽|𝑔1 (𝜌, 𝜏)|2
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(1.17)

Here, β is the coherence factor of the system, which depends on the coherence length and
stability of the laser, as well as the detection optics. This parameter is inversely
proportional to the number of detected modes of light (number of speckles detected) and
will depend entirely on the equipment and experimental set up.
By utilizing the diffusion approximation, G1 can be modelled by the correlation diffusion
equation that governs correlation transport through a turbid medium with a constant point
source S107,108:
[𝐷(𝑟, 𝑡)∇2 − 𝑣𝜇𝑎 (𝑟, 𝑡) − 𝑘𝐷2 (𝜏)] ∙ 𝐺1 (𝑟, 𝑡) = −𝑣𝑆(𝑟)

(1.18)

Recall that D is the diffusion coefficient of the medium (Equation 1.12), while 𝑘𝐷2 (𝜏) is a
function that accounts for the loss of correlation due to the motion of scatters109:
2

𝑘𝐷2 (𝜏) = 3𝜇𝑠′ 𝜇𝑎 + 𝛼𝜇 ′ 𝑠 𝑘02 〈𝑟 2 (𝜏)〉

(1.19)

Here, 𝑘0 = 2𝜋𝑛/λ is the wavenumber of the light (refractive index n and wavelength λ), α
is the ratio of moving scatterers (predominantly RBCs in living tissue) to the total number
of scatterers in the sample. 〈𝑟 2 (𝜏)〉 is the mean-square displacement of these moving
scatters during correlation time 𝜏, and depends on the flow model chosen during data
analysis. The most common flow model used in DCS analysis is the Brownian diffusion
model which assumes incoherent motion caused by multiple interactions of moving
scatterers. The Brownian displacement formula is given by108,109:
〈∆𝑟 2 (𝜏)〉 = 6𝐷𝐵 𝜏

(1.20)

Here, DB is the effective Brownian diffusion coefficient. Inputting Equation 1.20 into 1.19
results in:
2

𝑘𝐷2 (𝜏) = 3(𝜇𝑠′ 𝜇𝑎 + 2𝛼𝐷𝐵 𝜇𝑠′ 𝑘02 )

(1.21)

𝛼𝐷𝐵 is the value to be obtained as it is denoted as our blood flow index value (𝐵𝐹𝐼 = 𝛼𝐷𝐵 ).
Obtaining an estimate of 𝛼𝐷𝐵 requires computing G1, which can be accomplished with an
analytical solution to Equation 1.18 for a semi-infinite homogenous medium102,109,110:
𝐺1 (𝜌, 𝜏) =

3𝜇𝑠′ 𝑒 −𝑘𝐷(𝜏)𝑟1 𝑒 −𝑘𝐷(𝜏)𝑟2
[
−
]
4𝜋
𝑟1
𝑟2
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(1.22)

where 𝑟1 = (𝜌2 + 𝑧02 )1/2, 𝑟2 = (𝜌2 + (𝑧0 + 2𝑧𝑏 )2 )1/2, and 𝑘𝐷 (𝜏) is defined earlier. Here,
𝑧0 is the effective depth of the light source and is defined as the inverse of the reduced
scattering coefficient, 1/𝜇𝑠 ′. 𝑧𝑏 = 2𝐷(1 + 𝑅𝑒𝑓𝑓 )(1 − 𝑅𝑒𝑓𝑓 ) − 1 is the extrapolated
boundary. Reff is the effective reflection coefficient which is equal to 0.493, according to
Haskell et al.111 who found this value to be representative of measured tissue data at a
refractive index n of 1.4. The measurements of G1 as a function of 𝜏 can be fitted to yield
αDB using the known source-detector distance ρ, and measured (or assumed) values of 𝜇𝑠′
and 𝜇𝑎 .
Estimates of the blood flow index made by DCS have been shown to correlate with flow
measurements from other modalities including MRI techniques, TCD, and the
intravascular contrast technique described in Section 1.5.1112–115. It has also been validated
against clinical and pre-clinical expectations measured from tissue physiology102,114.
Similarly to CW and unlike TR-NIRS, DCS is not a depth sensitive technique; so the multilayer measurement described in Section 1.4.1 is usually utilized to distinguish extracerebral layers during CBF measurment116. One deterrent to DCS technology is the
measurement of CBF as a blood flow index (BFI) value which are in units of diffusion
(cm2/s) rather than blood flow (ml/min/100 g) or velocity (cm/s).

1.6 Combining NIRS and DCS
As mentioned previously, optical methods provide the unique ability to measure both StO2
and CBF through different techniques with sub-second temporal resolution. The ability to
take measurements at these speeds allow for the fast tracking of both these parameters
resulting in a better understanding of the underlying processes that govern CVR in the
proper maintenance of oxidative metabolism and brain health. The combination of both
will reveal information on the neurovascular coupling of StO2 and CBF as well provide an
in-depth understanding of CVR. A hybrid system such as this is not only relatively
inexpensive, but also portable such that it can be easily integrated into future research
prospects or eventual clinical use for continuous patient monitoring.
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The first paper to describe the use of NIRS and DCS together involved the intermittent
collection of oxygenation and blood flow data in an animal model back in 2001117.
Although the measurements were not made simultaneously, this study highlights the
advantages of this all-optics approach. The first to demonstrate both technologies in
humans was done in 2004118. In recent years, there have been several successful attempts
to simultaneously measure StO2 and CBF with the combination of CW-NIRS and DCS in
both infants and adults. Infants undergoing functional activity displayed repeatable
responses during simultaneous measurement with both systems, showcasing the
reproducibility of the devices and the lack of effect they have on one another after
modification119. Another study showcased similar responses in both oxygenation and CBF
between four adults to a hemodynamic stimulus during an 80 second measurement
period104. Broadband NIRS has been used simultaneously with DCS together as well using
actuating shutters to reduce cross talk in both animals and neonates120.
There are also published papers that describe the combination of the more sophisticated
FD-NIRS and DCS for simultaneous measurement of oxygenation and blood flow on
humans. Farzam et al.121 documents the optical and physiological characteristics of 30
healthy infants’ brains using both systems, taking note of differences in measurements
between males and females, brain hemispheres, and varying gestational age. Carp et al122
measured changes in blood flow and oxygenation during a 60-second forearm occlusion in
healthy adults after confirming their hybrid system’s capabilities on optical phantoms.
Putting a focus on better depth-sensitivity, TR-NIRS is a better choice than the CW and
FD counterparts. Both TR-NIRS and DCS have been used in conjunction to measure both
StO2 and CBF123,124 but published work on the combination of these two for truly
simultaneous measurement have only very recently come about79,125. One study considered
oxidative metabolism of patients after acute brain injury while the other examined the
accuracy and precision of the BabyLux Device; a commercial product designed to measure
hemodynamic parameters of infants using TR-NIRS and DCS technologies. There
certainly is interest in the use of both TR-NIRS and DCS together, but none of these studies
investigated StO2 and CBF dynamics in adults for assessing CVR.
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1.7 Research Objectives
This thesis will revolve around two main goals, the first is to develop a hybrid system
combining both TR-NIRS and DCS for non-invasive and simultaneous measurement of
StO2 and CBF within the same brain tissue volume. The choice of TR-NIRS over
conventional NIRS methods allows for the depth-sensitivity necessary to remove scalp
contamination in an effective way that does not depend on multiple detectors. DCS is a
preferred optical modality over the blood flow measurement techniques mentioned in
Section 1.5.1 for its non-invasiveness and ease of continuous measurement. Both of these
technologies were run together with the use of optical filters to minimize crosstalk between
the two. Crosstalk was evaluated on each system separately on phantoms of optical
properties similar to human tissue before simultaneous measurements with both systems
were performed.
After modifications allowing for these systems to collect simultaneous measurements were
completed, the next goal was to utilize the hybrid system on human subjects in order to
measure and characterize CVR with sub-second temporal resolution. The experiments
conducted on the participants involved hypercapnic periods to resolve a measurement of
CVR as well as a time component quantifying the rate of the response. The recorded
simultaneous increase in both CBF and StO2 was characterized and evaluated alongside
heart rate and blood pressure measurements recorded by a separate commercial device.
The introduction of a non-invasive hybrid system capable of measuring fast responses to
CBF and StO2 in the adult brain can potentially lead to a greater understanding of the
coupling between these two factors, CVR, as well as factors that can impair CVR in regards
to the normal aging process and potential methods of treatment. No such device exists for
adult use, and this is the first series of experiments that measure CVR with both TR-NIRS
and DCS simultaneously.
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Chapter 2
2.1 Cerebrovascular Reactivity Experiments
This study was approved by the Research Ethics Board the Western University Health
Sciences Research Ethics Board, which adheres to the guidelines of the Tri-Council Policy
Statement for Research Involving Humans. Written informed consent was obtained from
each subject prior to the experiment. The study involved twelve healthy adult participants
(9 males, 3 females; ages 24 to 53) with no neurological disorders.

2.1.1 Experimental Protocol
Each subject sat in a reclining chair and an individually customized gas mask was placed
over the subject’s mouth and nose (figure
2.1). The mask was made airtight by
sealing its edges with transparent film
dressing (TegadermTM, 3M, St. Paul,
USA). The mask was connected to a
computer-controlled gas delivery circuit
(RespirAct™; Thornhill Research Inc,
Toronto, Canada) described by Slessarev Figure 2.1: A participant wearing the gas mask with
et al126. The system is capable of the TR-NIRS/DCS probes secured to the forehead.
controlling end-tidal partial pressures of
CO2 and O2 (PETCO2 and PETO2,
respectively) via a prospective targeting
algorithm. The PETCO2 and PETO2 values
generated by the circuit have been shown

Figure 2.2: TR-NIRS/DCS probe holder (104x25 mm).
Fibre placements for the two systems are indicated by

to accurately reflect

arterial blood colour (Blue = TR-NIRS, Red = DCS). Detectors are
gasses127. Heart rate (HR) and arterial labeled D and sources S. Note, one detector position was
blood

pressure

were

monitored shared by both systems (half red, half blue).

continuously using a finger cuff device (Finapres Medical Systems, Enschede,
Netherlands).
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A custom-built probe holder (Figure 2.2) was placed on the forehead and secured by a
Velcro headband. The holder was designed using SpaceClaim, and 3D printed (TAZ 5,
LulzBot, Loveland, USA) with a thermoplastic polyurethane material (Sapphire NinjaFlex,
NinjaTek, Manheim, USA). Detection fibers for both subsystems were placed at short and
long source-detector distances to obtain measurements with different depth sensitivities.
The SDDs were 10 and 30 mm for TR-NIRS and 10 and 27 mm for DCS. The shorter SDD
is primarily sensitive to superficial, extra-cerebral tissues (i.e. scalp), while light detected
at the long SDD probes both cerebral and extracerebral tissues. The relative distances from
sources and detectors for the two systems were chosen to minimize crosstalk between the
systems. Aspects of this design, in particular the locations of the two detectors at 1 cm from
their respective source, were based on preliminary experiments involving tissue-mimicking
phantoms (data not shown). To ensure that both systems were interrogating the same brain
region, the detectors positioned at the longer SDDs shared the same location. During the
experiment, room lights were turned off and a black cloth placed around the probe holder
to minimize detection of ambient light.
The experimental protocol started with a 2-min period of normocapnia, followed by three
2-min periods of hypercapnia, each separated by a 5-min normocapnia period (Figure 2.3).
The hypercapnia target PETCO2 target was set to 15 mmHg above each subject’s
normocapnic PETCO2 value. TR-NIRS and DCS data were acquired continuously
throughout the cyclical PETCO2 protocol at a sampling rate of 3 Hz.

Figure 2.3: PETCO2 protocol consisting of three hypercapnic periods.
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2.1.2 Crosstalk Evaluation
In a subset of participants (N = 4), a series of initial tests were conducted to evaluate the
magnitude of crosstalk between the two systems prior to running the hypercapnia protocol.
With the probe holder placed on the forehead, data were collected from each system with
and without light emission from the other system. The protocol consisted of three 1-min
acquisitions: TR-NIRS data alone, TR-NIRS and DCS collected simultaneously, and DCS
data alone. The sequence was repeated three times. All measurements were made at a rate
of 3 Hz. DCS laser emission power was ~60 mW and TR-NIRS laser powers were 0.6 and
0.3 mW at 760 and 830 nm, respectively, which were set based on typically powers used
in the hypercapnia experiments.

2.2 Hybrid TR-NIRS/DCS System
Figure 2.4 illustrates the design of the hybrid system. The two subsystems are described in
detail in the following sections.

Figure 2.4: Schematic of the hybrid TR-NIRS/DCS system
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2.2.1 Time-Resolved Near-Infrared Spectroscopy
The system consisted of two picosecond pulsed diode lasers (LDH-P-C, PicoQuant, Berlin,
Germany) emitting at 760 and 830 nm with output powers less than 2.0 mW and a pulse
repetition rate of 80 MHz. An objective lens (NA = 0.25, magnification 10X, Olympus,
Japan) coupled light pulses from each laser head into a bifurcated multimode fiber bundle
(2 fibers; NA = 0.39, core = 400 µm; Fiberoptics Technology, Pomfret, USA) that guided
the light onto the skin surface. Diffusely reflected photons were collected by a fiber bundles
(NA = 0.55, core = 400 µm; Fiberoptics Technology, Pomfret, USA) at distances of 1 cm
from the source. Another fiber bundle of 121 optical fibers (NA = 0.22, core = 200 μm,
cladding = 220 μm, length = 0.5 m) was shared with the detection end of the DCS system
– as shown in Figure 2.3 – collected light at a distance of 3 cm. Each fiber guided collected
light to a hybrid photomultiplier detector (PMA Hybrid, PicoQuant, Berlin, Germany). To
mitigate signal contamination from the DCS laser, a short-pass interference filter (Spec
3551, 836.5 nm, dia = 25mm, Alluxa, Santa Rosa, USA) was placed between collimating
lenses (LA1131-B, LA1951-B, Newton, USA) in front of each of the three detectors as
shown in Figure 2.3. The output of each detector was sent to a TCSPC module (HydraHarp
400, PicoQuant, Berlin, Germany).
At the end of each study, the instrument response function (IRF) was measured to account
for instrument-related temporal light dispersion. This was done using a custom-built lighttight box that connected the emission fiber to a detection probe with a separation of 70 mm.
A piece of folded white paper was used to disperse the light before it entered the detection
probe. When necessary, neutral density filters were placed in front of the detector to avoid
saturating the detector. Data acquisition for this step was typically 60 seconds.

2.2.2 Diffuse Correlation Spectroscopy
The DCS system used a continuous-wave laser source emitting at 850 nm with a coherence
length greater than 10 m (DL852-100-SO; Crystalaser, Inc., Reno, USA). The laser was
coupled to a multimode fiber (NA = 0.22, core = 400 µm; Fiberoptics Technology, Pomfret,
USA) with approximately 60 mW of power at the end of the fiber. Reflected light was
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collected by four single-mode fibers (SMF-28e +, NA = 0.14, core = 8.2 μm, single-mode
cutoff wavelength at 1260 nm), one of which placed at distance of 10 mm from the
emission fiber and the remaining three placed at a distance of 27 mm as part of a common
ended bundle that also contained the fibers for TR-NIRS (Figure 2.3). Each fiber was
coupled to the input of a single photon counting module (SPCM-AQ4C; Excelitas Canada
Inc., Toronto, Canada). Due to the large difference in power between the DCS lasers and
TR-NIRS lasers (~60 mW versus < 2 mW), filters in front of the DCS detectors were not
required to block light from the TR-NIRS lasers. The output of each SPCM were relayed
to a counter/timer data acquisition board (PCIe6612; National Instrument, Austin, USA).
Photon counts were recorded and processed using in-house software developed on National
Instruments™ LabVIEW to generate the normalized intensity autocorrelation curves
(g2)128.

2.3 Data Analysis
2.3.1 Systemic Physiological Parameters
Steady-state baseline values of HR and mean arterial pressure (MAP) were obtained by
averaging data acquired over a one-minute period immediately preceding each hypercapnia
period. Measurements acquired over the second minute of each hypercapnic period were
chosen to characterize the average HR and MAP responses to increased PETCO2. Time
courses of relative changes in HR and MAP during each hypercapnic challenge were scaled
by their respective baseline value. These time series were smoothed with a 7.5 second
moving average (movmean, MATLAB).

2.3.2 TR-NIRS Data
2.3.2.1 Optical Properties
In order to determine baseline optical properties at both SDDs, the TPSFs measured during
the first 2 minutes of the experiment before the first hypercapnia period were averaged.
The mean TPSF was then fit with the diffusion equation for a semi-infinite homogeneous
medium after convolving with the measured IRF129 (fminsearch, MATLAB). Three
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parameters were extracted: μ𝑎 and μ'𝑠, and an amplitude factor that accounts for laser
power, detection gain, and coupling efficiency130. Figure 2.5 illustrates an example of a
normalized IRF and TPSF, and the best-fit of the model to the convolved TPSF, as well as
the fitting ranges used during analysis.

Figure 2.5: Normalized TPSF and IRF (left) and best fit of the model the data (right). The fitting range
(labeled with arrows) was set to 80% of the peak value on the ascending edge and 20% on the descending
edge.

The optical properties measured at 830 nm were used in the analysis of the DCS data
(Section 2.3.3).

2.3.2.2 Moment Analysis
The first three statistical moments were calculated from each TPSF determined from the
total photon count, average time of flight, and variance (i.e., N, <t>, V). While the total
photon count is trivial, the other two moments are calculated via Equation 2.1 and 2.2.
〈𝑡〉 =

(𝑥1 + 𝑥2 + 𝑥3 + ⋯ + 𝑥𝑛 )
𝑁

(2.1)

Here, 𝑥 represents the photon count measured at a given time bin, and 𝑛 is the total number
of bins.
[(𝑥1 − 〈𝑡〉)2 + (𝑥2 − 〈𝑡〉)2 + (𝑥3 − 〈𝑡〉)2 + ⋯ + (𝑥𝑛 − 〈𝑡〉)2 ]
𝑉=
𝑁
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(2.2)

Time courses of change in each moment (A, <t>, and V) at 760 and 830 nm were
determined relative to initial values (N0, <t>0, V0), which were extracted from baseline
TPSFs.
𝑁
∆𝐴 = −log ( )
𝑁0

(2.3)

∆〈𝑡〉𝑡 = 〈𝑡〉 − 〈𝑡〉0

(2.4)

∆𝑉𝑡 = 𝑉 − 𝑉0

(2.5)

These changes can be related to some change in absorption (Δμa) within the medium
through a sensitivity factor of individual moment. These are the mean partial pathlength
(MPP), the mean time sensitivity factor (MTSF), and the variance sensitivity factor
(VSF)85,131,132.
∆𝜇𝑎 =

∆𝐴
𝑀𝑃𝑃

(2.6)

∆𝜇𝑎 =

∆〈𝑡〉
𝑀𝑇𝑆𝐹

(2.7)

∆𝑉
𝑉𝑆𝐹

(2.8)

∆𝜇𝑎 =

Estimates of these sensitivity factors at SDDs of 1 and 3 cm were obtained from Monte
Carlo simulations using literature values of the optical properties (μa = 0.17 cm-1 and us =
8.0 cm-1)133. The changes in absorption were converted to changes in oxy- (ΔcHbO) and
deoxy-hemoglobin concentrations (ΔcHb) by solving a set of linear equations with the
known extinction coefficients of HbO2 and Hb:
∆𝜇𝑎 (𝜆) = 𝜀𝐻𝑏𝑂2 (𝜆) ∙ ∆c𝐻𝑏𝑂2 + 𝜀𝐻𝑏 (𝜆) ∙ ∆c𝐻𝑏

(2.9)

Here, 𝜀𝐻𝑏𝑂2 (𝜆) and 𝜀𝐻𝑏 (𝜆) are the molar extinction coefficients for oxy- and deoxyhemoglobin, respectively, at 780 and 830 nm. Time courses of ΔcHbO and ΔcHb were
generated for each of the three moments to assess depth-sensitivity. All time courses were
smoothed with a 4.5-s moving average with a zero-phase digital filter (filtfilt, MATLAB).
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2.3.3 DCS Data
Autocorrelation curves measured by the DCS system at the short and long SDD were fit
(fminsearchbnd, MATLAB) to the solution of the correlation diffusion equation for a semiinfinite homogenous medium (Equation 1.22) to extract estimates of β and αDB, where β
is the coherence factor and αDB is the diffusion coefficient, commonly referred to as the
blood flow index (BFI). The fitting range was set from a correlation time of 1 to 500 μs.
All fitting analysis was conducted using the μ𝑎 and μ'𝑠 values determined by TR-NIRS
during the entire measurement period. The values at 830 nm were used since the optical
properties are similar to those at 850 nm134. The subsequent BFI time courses were
smoothed with a 2nd order bandstop infinite impulse response filter (designfilt, MATLAB)
that removed higher frequencies between 0.1 and 1.5 Hz.

2.3.4 Detrending
Detrending was performed to remove linear drifts in the TR-NIRS and DCS data across
the 23-min experimental duration. For the TR-NIRS data, a linear trend line was fit (polyfit,
MATLAB) to four 1-min periods starting prior to each hypercapnic period and at the very
end of the protocol (i.e., starting at 1, 8, 15, and 22 minute marks; figure 2.6). This linear
trend line was then subtracted from the Hb and HbO2 time courses. For the DCS data, a
second-order quadratic trend line was used.

Figure 2.6: Normalized simulated signal before and after detrending. Red regions depict the four 1-minute
baseline periods chosen for linear fit.
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2.3.5 Measuring Cerebrovascular Reactivity
The three hypercapnia periods were averaged to produce one 7-min time course per subject
for both the hemoglobin concentrations and CBF. Steady-state CVR was defined as the
mean signal (𝛥𝑆(𝑡)) change per mmHg change in PETCO2 during hypercapnia:
𝐶𝑉𝑅 =

𝛥𝑆(𝑡)
𝛥𝑃𝐸𝑇 𝐶𝑂2 (𝑡)

(2.10)

To characterize the reactivity of HbO2, Hb and CBF to hypercapnia, the measured step
change in PETCO2 (PETCO2) was convoluted with a hemodynamic response function
(HRF) and fit to each of the ΔcHbO, ΔcHb, and BFI time courses10:
𝛥𝑆(𝑡) = 𝐴 ∙ [𝛥𝑃𝐸𝑇 𝐶𝑂2 (𝑡) ∗ 𝐻𝑅𝐹(𝑡)],

(2.11)

where ∗ symbol denotes the convolution operator, A is an amplitude term and HRF is
defined as follows:
𝐻𝑅𝐹(𝑡, 𝑡𝑜 , 𝜏) =

1 −(𝑡−𝑡𝑜 )
𝜏
𝑒
𝑁

(2.12)

The HRF is defined by an exponential decay function with a rate constant defined as the
dynamic component (τ) as well as a time-shift (to). N is a normalization constant equal to
the area under the curve. The dynamic component is a metric indicating how rapidly a
vascular bed can respond to a step change in PCO2, i.e. the speed of the response, while
the time-shift represents the delay in the response. Best-fit estimates of τ and to were
obtained using by a bounded optimization routine (fminsearchbnd, MATLAB), which the
lower and upper bounds to were set to 0 and 120 s. Due to the lower signal-to-noise ratio
(SNR) of DCS, in many of the cases it was necessary to set to manually. For τ, the lower
bound = 0.6 s (twice the sampling rate) and an upper bound = 180 s. In cases in which the
fitting routine reached the upper bound, the model was not considered an accurate
representation of the time course. As a result, these particular datasets were not included
in subsequent data analysis.
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The amplitude term is updated with each successive iteration of the fitting. It is defined by
the slope between the signal S(t) and the convolution between PETCO2 and the HRF10:
𝐴=

𝑆(𝑡)
𝛥𝑃𝐸𝑇 𝐶𝑂2 (𝑡) ∗ 𝐻𝑅𝐹(𝑡)

(2.13)

The fitting was performed over a time window that encompassed the expected hypercapnia
response (i.e. from the initial response to 𝛥𝑃𝐸𝑇 𝐶𝑂2 (𝑡) to the rapid decent when PETCO2
returns to its predefined normocapnic value). In some cases, a decline in S(t) was not
evident at the end of hypercapnia. In these cases, the fitting ranged stopped at the end of
the hypercapic period. These two possible fitting ranges are shown in Figure 2.8. The
analysis was conducted using ΔcHbO and ΔcHb time courses derived from each of the three
moments for TR-NIRS data acquired at SDD = 3 cm and BFI time courses acquired at both

Normalized Simulated Response

SDDs.

Full Response Fit

Reduced Range

Time (minutes)
Figure 2.7: Coloured in green: Range of whole hypercapnia response. Coloured in red: Truncated range,
stopping at the end of hypercapnia.
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2.3.6 Correlation Analysis
Correlation analyses were performed to investigate similarities between hemoglobin and
CBF times courses. First, an assessment of the depth sensitivity of DCS was performed by
correlated the hypercapnia-induced BFI time course (defined from the start of hypercapnia
to 1 min after hypercapnia) to the corresponding ΔcHbO and ΔcHb time courses obtained
from A, <t>, and V separately. This analysis was only conducted for data sets obtained
at the longer SDD. Second, the impact of signal contamination from the scalp in the TRNIRS data acquired at SDD = 3 cm was assessed. For this analysis, the ΔcHbO time course
derived from A at SDD = 1 cm was chosen to represent the scalp signal since the
combination of change in number of photons with the shortest SDD provides the greatest
sensitivity to scalp oxygenation. This time course was subsequently correlated to the ΔcHbO
time courses derived from each of the three moments at the longer SDD.

2.3.7 Statistical Analysis
MATLAB was used for all statistical analysis. The average heart rate and arterial pressure
baseline values among all measured subjects were compared with their subsequent
hypercapnic values with a two-sample t-test (ttest2, MATLAB).
A multivariable analysis was employed to determine any possible significance differences
in CVR between measurements made from each of the three moments and the values
collected from Hb and HbO2 (manova, MATLAB). Afterwards, a second statistical test
was conducted between any two pairs of measurements with a straight forward two-sample
t-test (ttest2, MATLAB). This was also performed with the average MSE values measured
from the TR-NIRS fitting algorithm as well as the time-shift averages and dynamic
component averages measured from both systems. Correlation averages between the TRNIRS and DCS measurements underwent a similar procedure.
P-values equal or below 0.05 denoted significant difference and noted in the results section.
All error bars from presented figures represent standard error of the mean while all average
values are presented as mean ± standard deviation.
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Chapter 3
3. Results
3.1 Simultaneous TR-NIRS/DCS Data Acquisition
TPSFs collected with the TR-NIRS system with and without emission from the DCS laser
are presented on Figure 3.1. These results illustrate the contamination from the DCS source
at full power (approximately 60 mW) as evident by the rise in the background signal. The
magnitude of contamination averaged across four participants and both wavelengths was 9
± 5% at SDD = 1 cm and 3 ± 1% at SDD = 3 cm. Included in the figure are the corrected
TPSFs after subtracting the background signal.

Figure 3.1: TPSFs recorded at 830 nm, SDD = 1 and 3 cm, and with and without emission from the DCS
laser. Data are from one subject. To the right are the same TPSFs after correcting for the background signal.

Figure 3.2 presents autocorrelation curves recorded by the DCS system with and without
emission from the TR-NIRS lasers, which were set at power levels typically used in human
applications (i.e., approximately 0.6 and 0.3 mW for the 760 and 830 nm lasers,
respectively). Data are presented for all four subjects. Average difference in estimated BFI
values between the two conditions was 9 ± 5% at SDD = 1 cm and 3 ± 1% at SDD = 2.7
cm.
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Figure 3.2: Autocorrelation curves recorded on the forehead at SDD = 1.0 (left four plots) and 2.7 cm (right
four plots). Curves are presented under the control and test conditions (i.e. without and with emission from
the TR laser, respectively).

3.2 Cerebrovascular Reactivity Experiments
3.2.1 Gas Delivery
Figure 3.3 displays the end-tidal PCO2 time course for a single subject. The computerized
gas controller produced highly reproducible PETCO2 changes for all subjects. The average
increase in PETCO2 among all subjects was 14 ± 2 mmHg, within error of the target 15

End-tidal PCO2 (mmHg)

mmHg.

Figure 3.3: PETCO2 time course from one subject. Each point above represents the end-tidal PCO2 measured
during a single breath.
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3.2.2 Systemic Physiological Parameters
Of the 12 participants, heart rate (HR) and mean arterial pressure (MAP) were successfully
measured in 10 throughout the entire 23-minute period. Complete data sets were not
collected for two subjects due to technical challenges with the Finapres software. Tables
3.1 and 3.2 outline the average HR and MAP from each subject measured, during the one
minute prior and latter half of each hypercapnia period. Since measurement was incomplete
for subject #6 and #9, their values were omitted from these tables.
Hypercapnia
Subject
1
2
3
4
5
7
8
10
11
12
Average

1
Before
60
61
70
87
59
47
73
66
72
58
65 ± 10

2
During
66
63
69
97
53
55
100
63
76
69
71 ± 15

Before
69
59
69
87
51
51
76
68
72
57
66 ± 11

3
During
71
60
70
99
52
53
78
63
75
69
69 ± 13

Before
69
59
72
88
51
51
73
66
70
57
66 ± 11

During
69
64
69
104
57
53
76
64
72
68
70 ± 13

Table 3.1: Heart Rate (BPM) before and during hypercapnia for each of the three hypercapnia periods for
10 subjects. Average and standard deviation listed on bottom row.
Hypercapnia
Subject
1
2
3
4
5
7
8
10
11
12
Average

1
Before
69
105
74
85
80
96
76
103
86
90
86 ± 12

2
During
77
109
84
93
84
105
93
102
99
110
96 ± 11

Before
72
100
75
83
82
97
81
100
85
86
86 ± 9

3
During
77
100
83
97
89
109
89
103
94
105
95 ± 10

Before
69
99
74
89
83
94
84
105
85
88
87 ± 10

During
81
105
82
103
90
103
88
106
97
107
96 ± 10

Table 3.2: Mean arterial pressure (mmHg) before and during hypercapnia for each of the three hypercapnia
periods for 10 subjects. Average and standard deviation listed on bottom row.
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Figure 3.4 presents the average HR and MAP time courses for these 10 subjects to illustrate
their respective responses to hypercapnia. In both cases, the time course across the three
hypercapnic challenges was condensed to one 7-minute plot consisting of 0.5 minutes of
baseline and 2 minutes of hypercapnia, followed by a 4.5-minute recovery period. The
average increases in HR and MAP in each of the three hypercapnia periods are displayed
on Figure 3.4. Averaged across all measured participants, the increase in MAP is
significantly significant.

Figure 3.4: Heart rate and mean arterial pressure averaged across 10 subjects. The shaded background
surrounding the solid line represents the standard error. Blue region represents the 2-min hypercapnic
challenge.

3.2.3 Oxygenation and Blood Flow Responses
Of the twelve subjects, two were omitted from the data analysis. One because of poor skinto-probe contact, which resulted in poor SNR, and the other participant could not tolerate
a 15 mmHg increase in end-tidal PCO2. Figure 3.5 displays oxygenation and blood flow
time courses from a single subject. Every subplot includes the PETCO2 time course to
demonstrate the relationship between it and the recorded signals. First two rows display
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TR-NIRS data collected at the longer SDD. Hemoglobin time courses based on changes in
the number of photons (zeroth moment), mean time of flight (first moment) and variance
(second moment) are shown to illustrate the effects of moment analysis. The last row of
subplots includes the corresponding CBF time courses derived from the DCS
measurements at the two SDDs, and the HbO2/Hb time course derived from the number of
photons recorded by TR-NIRS at SDD = 1 cm. The latter would have the greatest
sensitivity to oxygenation changes in the scalp.

Figure 3.5: TR-NIRS and DCS data from one participant. Top two rows display temporal changes in HbO2
and Hb concentrations as derived from moment analysis (N, <t>, V) applied to TPSF data acquired at SDD
= 3.0 cm. Bottom row displays CBF time courses at SDD = 1.0 and 2.7 cm, respectively, measured by DCS
as well as the change in HbO2 and Hb concentration measured at SDD = 1.0 cm. The light blue line is the
end-tidal PETCO2 and the black line is the best-fit of the model using PETCO2 as the input.
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To illustrate the differences in responses between participants, Fig 3.6 presents the same
time courses from another subject. In this case, the signals show more consistency with
each other with a closer resemblance to the PETCO2 function.

Figure 3.6: A second example of TR-NIRS and DCS data acquired from another subject. Data are presented
in the same format as described for Figure 3.5.

Figure 3.7 displays the average Hb and HbO2 concentration changes resulting from the
hypercapnic challenge across the 10 participants. Time courses are presented for both
source-detector distances (1 and 3 cm) and for each of the three moments (N, <t>, V). For
all participants, the responses to the three hypercapnic challenges were averaged to produce
one 7-minute time course. The corresponding time courses for the change in the total
hemoglobin concentration are shown in Figure 3.8.
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N

<t>

V

Figure 3.7: Average responses of oxy- and deoxy-hemoglobin (solid lines) to the 2-min hypercapnic
challenge (indicated by the shaded blue region). Time courses were averaged across 10 subjects and the three
periods of hypercapnia. Shaded areas surrounding each line represents the standard error of mean.

N

<t>

V

Figure 3.8: Total hemoglobin response to the 2-min hypercapnic challenge (indicated by the shaded blue
region). Time courses were averaged across 10 subjects and three periods of hypercapnia. Shaded background
surrounding each line represents the standard error of mean.
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The average CVR measurements obtained separately from HbO2 and Hb (SDD = 3 cm) are
presented in Figure 3.9. Multivariate ANOVA revealed a significant difference (p < 0.01)
between CVR values measured by HbO2 and Hb; however, there was no significant
difference between moments. Table 3.3 displays the individual CVR measurements of each
subject. Two CVR values from the variance data sets were omitted as their corresponding
time courses had very low SNR.

*

*

Figure 3.9: CVR measurements measured from each moment, determined from HbO 2 and Hb
concentrations. Error bars represent standard error of the mean. Stars (*) denote significant difference
between oxy and deoxy from the first and second moments.

Subject
1
2
3
4
5
6
7
8
9
10
Average

CVR measured from N
(%/mmHg)
HbO2
Hb
0.178
0.118
0.060
0.025
0.132
0.284
0.249
0.119
0.171
0.059
0.137
0.036
0.061
0.033
0.203
0.030
0.133
0.064
0.267
0.212
0.16 ± 0.07
0.10 ± 0.08

CVR measured from <t>
(%/mmHg)
HbO2
Hb
0.142
0.080
0.152
0.072
0.760
0.054
0.139
0.187
0.297
0.173
0.263
0.125
0.098
0.085
0.225
0.034
0.138
0.030
0.224
0.205
0.24 ± 0.20
0.11 ± 0.06

CVR measured from V
(%/mmHg)
HbO2
Hb
0.115
0.024
0.195
0.082
0.114
0.037
0.084
0.104
0.076
0.262
0.137
0.102
0.041
0.143
0.040
0.112
0.150
0.111
0.14 ± 0.05
0.07 ± 0.04

Table 3.3: CVR (ΔμM/mmHg) derived from HbO2 and Hb measurements at the 3 cm source-detector
distance. Average and standard deviation listed on bottom row. Omitted CVR values are labeled as ‘-.’
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Figure 3.10 displays the 7-minute average CBF time courses collected by DCS system at
both the long and short SDD.

Figure 3.10: CBF response to the 2-min hypercapnic challenge (indicated by the shaded blue region). Time
courses were averaged across 10 subjects and three periods of hypercapnia. Shaded areas surrounding each
line represents the standard error of mean.

The average CVR obtained from the blood flow index change was 3 ± 3 %/mmHg and 4 ±
3 %/mmHg at the short and long SDD respectively. The measurements of each individual
subject are presented in Table 3.4.
Subject
1
2
3
4
5
6
7
8
9
10
Average

CVR measured from change in BFI
at 1.0 cm SDD (%/mmHg)
8.7
0.4
6.2
2.0
2.2
1.3
1.8
8.2
1.4
0.9
3±3

CVR measured from change in BFI
at 2.7 cm SDD (%/mmHg)
5.3
1.9
13.2
2.0
4.5
1.7
2.2
3.3
1.8
3.3
4±3

Table 3.4: CVR (%/mmHg) derived from blood flow index measurements at the 1.0 and 2.7 cm sourcedetector distances. Average and standard deviation listed on bottom row.
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The following three box plots display the results of the fitting procedure applied to the
HbO2 and Hb data separately. Two datasets from the second moment (HbO2: Subject 5,
Hb: Subject 9) were omitted from all box plots, averages and statistical analysis due to low
SNR.

Figure 3.11: From left to right: average MSE value from the fitted model, average time shift, and average
dynamic component. Red = HbO2, Blue = Hb. Outliers represented by grey crosses. One outlier on the MSE
plot for Oxy-Hb <t> had a value of 1.44, which is represented by the red cross. For the dynamic component,
the number of stars (*) beside each moment on the abscissa indicates the number of times the fitting procedure
reached its upper limit of 180 s.

Multivariate ANOVA revealed a significant difference in MSE between HbO2 and Hb, but
not between the moments despite the trend downwards in higher moments. In addition,
there was a significant difference between the time shift values obtained from the 3
moments, which was like due to the large values measured at the zeroth moment. There
were no significant differences in the dynamic component values.
Averages values of the time-shift and the dynamic component for the three moments are
provided in Table 3.1. The mean dynamic component values do not include individual
values that reached the upper limit of 180 seconds. Time-shift and dynamic component
measurements for the corresponding CBF responses (i.e. from DCS) at both SDD values
are given in Table 3.2. The distribution of the measurements is shown in Figure 3.13.
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Moment
HbO2
Hb

N
23 ± 32
45 ± 62

Time-shift (sec)
<t>
17 ± 26
6±6

V
7±6
8±7

Dynamic component (sec)
N
<t>
V
35 ± 38
43 ± 18
32 ± 16
30 ± 33
38 ± 21
33 ± 28

Table 3.5: Average and STD of the time-shift and dynamic component generated from the HbO 2 and Hb
time courses.
Time-shift (sec)
Distance

1.0 cm
39 ± 48

Dynamic component (sec)
1.0 cm
2.7 cm
32 ± 17
33 ± 18

2.7 cm
12 ± 8

Table 3.6: Average and STD of the time-shift and dynamic component generated from the CBF time courses.

There was a large difference between the mean time-shift estimates derived from DCS data
acquired at the two SDDs; however, this difference did not reach statistical significance.
This was attributed to the very large estimates (over 60 s) obtained at the short SDD for
three subjects. One example is illustrated in Figure 3.6.

Figure 3.12: Time-shift (left) with dynamic component values (right) derived from DCS data acquired at
SDD = 1 and 2.7 cm.

Figure 3.13 shows the correlation between hypercapnia-induced changes in blood flow and
hemoglobin concentration for one subject. For this analysis, the hemoglobin changes
derived from N, <t>, and V are each plotted against the concurrent DCS time course for a
3 min window starting with the beginning of the hypercapnia period. These correlations
plots are derived from the time courses presented in Figure 3.6. Figure 3.14 displays the
average correlation values across all subjects. Multivariable analysis revealed a statistical
difference between moments due to the smaller correlation values for the zeroth moment
with no significant difference between the correlation values derived from HbO2 and Hb.
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Figure 3.13: Correlation plots for one subject, comparing DCS CBF values to TR-NIRS oxy and deoxy
concentrations at the long SDD. The green circle marks the start of hypercapnia and black circle marks 3
minutes afterwards.

Figure 3.14: Average correlation values comparing DCS CBF time courses to corresponding oxy and deoxy
concentrations time courses (SDD = 3 cm). Error bars represent standard error (N = 10).

Figure 3.15 presents the correlation of the HbO2 time course generated from the changes
in the number of photons measured at SDD = 1 cm (i.e. the scalp response) to the
corresponding HbO2 time courses generated from each of the three moments at SDD = 3
cm. This analysis was conducted for the 4.5-minute period after hypercapnia and was
performed to investigate correlations between scalp effects and HbO2 changes measured at
the longer SDD. Although the correlation appeared to diminish for higher moments, this
trend was not statistically significant.
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Figure 3.15: Correlation values between HbO2 time courses measured at SDD = 1 and 3 cm. HbO2 measured
at SDD = 1 was derived from N as it has the greatest sensitivity to scalp, while HbO2 measured at SDD = 3
cm was derived from N, <t>, V individually. Subscripts denote the SDD. Error bars represent standard error.

Figure 3.16 presents relative changes in CBF, HbO2 and Hb at the long SDD. The
hemoglobin time courses were generated from the change in variance since the higher
moment had the greatest sensitivity to cerebrovascular reactivity. For illustration purposes
only, the Hb time course has been inverted. CVR estimates derived from relative changes
in HbO2 and Hb concentration were 3.4 ± 2.6 and 3.0 ± 1.9 %/mmHg, respectively. The
corresponding CVR derived from DCS data acquired at 2.7 cm was 3.5 ± 3.6 %/mmHg.

Figure 3.16: Average relative changes in CBF, HbO2 and Hb plotted alongside PETCO2. The hemoglobin
changes were derived from the change in variance and the Hb time course was inverted for display purposes.
Note that the time courses are presented without corresponding error bars.
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Chapter 4
4. Discussion
This study presents the development and optimization of a hybrid optical system for
characterizing dynamic CVR in adults. Given the sensitivity of the cerebral circulation to
arterial CO2, CVR is a well-established metric of cerebrovascular health, with studies
reporting reduced CVR related to age, cerebrovascular diseases and dementia7,135. Given
the advantages of optical methods in terms of low-cost, high temporal resolution, and
ability to measure multiple hemodynamic parameters, the current study focused on
assessing the reliability of a hybrid TR-NIRS/DCS system for simultaneous monitoring of
the cerebral blood flow and oxygenation responses to a step change in PETCO2. The first
main objective was to assess the impact of extra-cerebral signal contamination considering
it is the primary source of error with these optical methods. For the TR-NIRS data, this was
primarily achieved by moment analysis, while for DCS, blood flow data were acquired at
two SDDs. The second objective was to evaluate if the dynamic responses could be
adequately characterized by a simple single-exponential response function initially
proposed for BOLD fMRI10. The main finding of the study was that both TR-NIRS and
DCS have sufficient depth sensitivity to produce reliable CVR responses that reflected the
expected time courses reported in previous BOLD studies.
Simultaneous acquisition of DCS and NIRS data required minimal crosstalk between the
two systems. Initial tests using tissue-mimicking phantoms indicated that the DCS laser
increased the background signal for recorded TPSFs by less than 3% and similarly the two
pulsed lasers caused less than a 1% deviation in estimated BFI values. The in vivo tests
indicated larger errors for both sets of measurements: contamination of 3 ± 1% for TR
NIRS at SDD = 3 cm and a mean deviation in BFI of 3 ± 1% at SDD = 2.7 cm. The most
likely explanation for the increase in these errors was variability in probe-to-skin contact
(e.g. Subject 4 in Figure 3.2); however, the magnitude of contamination for both systems
remained relatively small, mean differences of less than 10% for all SDDs.
During the cardiovascular reactivity experiments, hemoglobin concentration time courses
were derived from the total photon count, mean time of flight, and variance data from the
measured TPSFs. The variance dataset (particularly Hb) provided the closest resemblance
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to the expected response, demonstrated by the left plot on Figure 3.11 which displays the
mean squared error between the signal and the fitting. This figure illustrated each data set’s
agreement to the expected model, although not significant, there is a notable decrease in
MSE between the lower and higher moments. The difference in MSE between Hb and
HbO2 also agreed with previous work that described Hb as a better biomarker for brain
activation than HbO249. In addition, the correlation between the scalp HbO2 response with
the measurements made at the long SDD after hypercapnia was higher at the lower
moments which indicated the similarities between the scalp response and the measurements
derived from the scalp-sensitive total photon count measurements. HbO2 measurements
were used for this demonstration as this chromophore is more affected by extracerebral
effects. Furthermore, concentrations derived from the second moment (variance data)
contained the least intersubject variability as illustrated by Figure 3.7, indicating high
repeatability and reliability in response measurement. This is due to the relatively fewer
extra-cerebral artifacts in this dataset. This evidence suggests that the variance data is
reliable and highly representative of the cerebral tissue, so the discussion will focus on
these time courses taken from this moment at the long SDD. This also provides valuable
insight into the benefits of the temporal information collected by the sophisticated TRNIRS system. It is important to note that the zeroth moment is still a useful metric to
measure scalp contamination at the short distance and that the first moment can offer higher
SNR and thus can often be a better choice over variance data in some applications88.
In contrast to the hemoglobin time courses that demonstrated noticeable differences at the
two SDDs, the BFI time courses collected at SDD = 1 and 2.7 cm were very similar. It is
possible that a portion of signal measured at the short SDD could be from brain tissue but
this is not an expected result as previous work have reported very little change in scalp
blood flow during hypercapnia measured from both DCS and Doppler flowmetry102. The
sensitivity of the brain at this short SDD should be under 1%104. The systemic scalp
response could have had a large effect on the long SDD as it has been shown that the
extracerebral contamination in a CBF measurement collected by DCS is 31 ± 47% at an
SDD of 3 cm136. Regarding depth-sensitivity, although the BFI measurements do not share
the same time-dependent analysis techniques as the TR-NIRS system, there is some inherit
depth-sensitivity attributed to the large difference in CBF from the cortex compared to
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extra-cerebral tissue. The correlation between the blood flow response and the Hb/HbO2
response at all three moments (Figure 3.14) displays the highest correlation at the first and
second moment confirming the depth-sensitivity of the DCS system. This matches prior
research which have demonstrated with both Monte Carlo simulation and in vivo
measurement that DCS measurements do have higher brain sensitivity compared to CWNIRS measurements (reliant on detection intensity measurements, i.e. total photon
count)104. Time-resolve DCS is an emerging technique and has the potential of
discriminating between photon path lengths and thus improving depth-sensitivity137, and
has been applied successfully in vivo on the human head138. However, the use of gated
detectors decrease efficiency, leading to lower SNR and longer acquisition time139. With
low temporal resolution such as 3 seconds per measurement140, it is very challenging to
monitor dynamic changes in blood flow. In the future, to improve depth sensitivity with
the current system, layered analytical models could be incorporated rather than the
homogeneous model used in the current analysis.
Systemic monitoring indicated that both heart rate and blood pressure increased during
hypercapnia. The average change in HR among all subjects displayed a slow return back
to baseline after hypercapnia ended (Figure 3.3), similar to the scalp response measured by
the TR-NIRS system at the short SDD. The slower systemic response compared to the
cerebral response is a demonstration of the body’s prioritization of the brain. It is important
to note that CO2 inhalation can naturally cause a fear or panic-like response141. This may
have played a factor in the increased heart rate. Mean arterial pressure also increased during
hypercapnia at a quicker rate, as expected as this increase in blood pressure is meant to
provide higher CBF changes than vasodilation may be able to provide alone during
hypercapnia142. If vasodilation reaches maximum, an increase in perfusion pressure
passively raises CBF further to meet the required amounts of energy when necessary. This
change in MAP may have not occurred with a lesser hypercapnic challenge143.
The CVR measurements from the TR-NIRS system (Figure 3.9), display a greater increase
in HbO2 in response to hypercapnia than the decrease in Hb. This is due to the dilation that
is occurring within the brain, allowing for an increase in total hemoglobin (Figure 3.8),
resultant from the larger amount of incoming HbO2 entering the microvasculature during
hypercapnia to nourish the cells than there is Hb leaving the microvasculature49. These
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CVR measurements, once converted to relative percentages from baseline (3.4 ± 2.6 and
3.0 ± 1.9 %/mmHg determined from HbO2 and Hb concentration respectively) showed no
statistical difference compared to the CVR measurements acquired from CBF measured at
the long SDD (3.5 ± 3.6 %/mmHg). These values are similar to CVR measurements found
in literature for healthy individuals144–146. Since lower CVR values have been measured in
patients suffering from age-related diseases such as Alzheimer’s4,7,17,147,148, it is important
to note that our system could be used as a research tool for such patients.
The speed of the response measured by the dynamic component parameter was similar
between all metrics: HbO2 (32 ± 16 s), Hb (33 ± 28 s), and the CBF measured from both
the short (35 ± 17 s) and long SDD (33 ± 18 s). These values are within error to values
measured from healthy participants in previous step-function hypercapnia studies with
BOLD-MRI10,149,150. Although the dynamic component of the response has not yet been
studied in a patient population, slower responses to hypercapnia has been indicative of
disease states151. This could allow for the application of the dynamic component parameter
as a sensitive metric to differentiate healthy from functionally impaired brain tissue.
The estimated time-shift was 7 ± 6 and 8 ± 7 seconds from the HbO2 and Hb response
respectively (V, Table 3.1). This is within error to the 12 ± 8 second average estimate
measured from the CBF response at the long SDD (Table 3.2). These values are expected
as the time-shift should generally be 12 seconds or less152 considering the idealized cerebral
response. Interestingly, the time shift measured from CBF was much greater at the short
SDD, but this was attributed to the very large estimates (over 60 s) obtained from 3
participants. In this case, the measured response is not from the brain, but likely from the
scalp. In addition to the previously mentioned metrics, differences in this time-shift value
measured by the hybrid optical system may be able to differentiate patients with
cerebrovascular disease from the healthy population as a delay in response has been
measured in disease population153.
Although both systems produced similar results, it is important to understand that the
combination of the two is what furthers the understanding of the coupling between blood
flow and oxygenation. With both measurements recorded simultaneously, this system can
allow for this coupling to be further researched in a number of different patient populations.
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There were a few potential limitations to the study. First, the homogeneity of the DCS
model does not accurately reflect the heterogenous medium that is the human head. A
multi-layer model would have provided better depth sensitivity and may have offered
greater differences between the time courses measured at the short and long SDD. In the
future, such a model should be implemented. Another potential limitation is that the
experiments conducted were only focusing on one level of hypercapnia, +15 mmHg of
PETCO2. It may have been interesting to look at the responses at different PETCO2 levels
and see if the contamination varies. Future experiments can focus on a slow increase of
CO2 (i.e. a ramp function) or perhaps different magnitudes of hypercapnia.
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Chapter 5
5. Conclusion
The work presented in this thesis describes the development and demonstration of a hybrid
TR-NIRS/DCS system capable of measuring cerebral oxygenation and blood flow
simultaneously. Optical filters were incorporated into existing systems allowing them to
run simultaneously with minimal cross talk, assessed with the measurement of phantoms
and in vivo. Then, with 10 participants, both cerebral oxygenation and blood flow were
independently measured by each subsystem to provide a detailed analysis of their
cerebrovascular reactivity. Decades of research has investigated the combination of NIRS
and DCS technologies to measure both oxygenation and blood flow data but very few
studies have managed to accomplish simultaneous measurement. In most cases, a simpler
form of NIRS (continuous-wave or frequency-domain) was used that does not provide
depth information like TR-NIRS. In addition, in vivo studies were mostly limited to animal
or neonatal research. With the successful measurement and analysis of dynamic CVR from
both HbO2 and CBF in adult subjects, this hybrid system opens a host of applications for
the immediate future. This system can work alongside other modalities such as fMRI, PET
and Doppler ultrasound as it is a relatively low-cost research tool capable of studying
dynamic CVR. Future studies utilizing the system could put a focus on the aging brain or
patients with vascular disease.
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